Studies from the same group have found that HORMAD1-expressing cancer cells have decreased the efficiency of homologous recombination (HR) repair and increased sensitivity to cisplatin and PARP inhibitors (PARPi)12, suggesting that aberrantly expressed HORMAD1 compromises HR and promotes response to chemotherapy. The gene discussed is HORMAD1; the disease is cancer.